Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Dyne Therapeutics, Inc.

DYN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$18.62

▲ +3.04%

Market Cap $3.49B · Vol 2.17M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.49B

Mid Cap

Div Yield

N/A

EPS Growth

-8.00%

YoY

RSI (14)

67.51

Momentum

Beta

1.17

vs Market

52W High

$27.29

31.77% below

52W Low

$14.12

31.87% above

Volume

2.17M

Avg 1.08M

P/B

3.32

Price-to-book

ROE

-55.71%

Return on equity

Free Float

94.92%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Dyne Therapeutics, Inc. (DYN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does DYN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.63%

+11.90%

-29.07%

+5.74%

YTD

-4.81%

+1.42%

+114.02%

+25.64%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-446,214,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-55.71%
ROA · ROIC	-47.52% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.32
P/FCF	N/A
EPS Growth	-8.00%
Outstanding Shares	187.39M

Technical Indicators

50-Day SMA	$17.57
200-Day SMA	$19.33
RSI (14)	67.51
Beta	1.17
52-Week High	$27.29
52-Week Low	$14.12

Volume Today	2.17M
Avg Daily Volume (30D)	1.08M
Relative Volume	2.00x
Volatility (10D)	58.75
Volatility (30D)	57.06
Free Float	94.92%

Analyst Consensus

BUY

Current Price $18.62

Mean Target $36.07

52W Low$14.12 52W High$27.29

Current

Target

$14.12 $27.29

Current Analyst target

+93.72% upside potential · 17 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00NSGPJF8

ISINUS26818M1080

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.27% ARGX.BR argenx SE +4.66% ARGX argenx SE +3.78% GMAB.CO Genmab A/S +3.80% GMAB Genmab A/S +4.05%

Company Profile

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.